Use of ezetimibe in the treatment of familial hypercholesterolemia in children and adolescents;Uso de ezetimibe en el tratamiento de la hipercolesterolemia familiar en niños y adolescentes

Anales de Pediatria

Volumn 77, Issue 1, 2012, Pages 37-42

  Araujo, M B ^a   Botto, P M ^a   Mazza, C S ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Cholesterol; Ezetimibe; Familial Hypercholesterolemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADOLESCENT DISEASE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FAMILIAL HYPERCHOLESTEROLEMIA; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MONOTHERAPY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LONGITUDINAL STUDIES; MALE; RETROSPECTIVE STUDIES;

EID: 84863524483     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2011.11.007     Document Type: Article

References (20)

1. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol and smoking: a preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990; 264:3018-24.
2. H.C. McGill Jr., C.A. McMahan, and A.W. Zieske Effects of nonlipid risk factors on atherosclerosis in youth with a favourable lipoprotein profile Circulation 103 2001 1546 1550
3. W.P. Newman III, D.S. Freedman, and A.W. Voors Relationship of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study N Engl J Med 314 1986 138 144
4. G.S. Berenson, S.R. Srinivasan, and W. Bao Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study N Engl J Med 338 1998 1650 1656
5. E.M. Tuzcu, S.R. Kapadia, and E. Tutar High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound Circulation 103 2001 2705 2710
6. C.A. McMahan, S.S. Gidding, and Z.A. Fayad Risk scores predict atherosclerotic lesions in young people Arch Intern Med 165 2005 883 890
7. S. Tonstad, and L. Ose Colestipol tablets in adolescents with familial hypercholesterolaemia Acta Paediatr 85 1996 1080 1082
8. S. Tonstad, M. Sivertsen, L. Aksnes, and L. Ose Low dose colestipol in adolescents with familial hypercholesterolaemia Arch Dis Child 74 1996 157 160
9. S. Tonstad, J. Knudtzon, and M. Sivertsen Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia J Pediatr 129 1996 42 49
10. B.W. McCrindle, M.B. O'Neill, G. Cullen-Dean, and E. Helden Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial J Pediatr 130 1997 266 273
11. M. Van Heek, C.F. France, D.S. Compton, R.L. McLeod, N.P. Yumibe, and K.B. Alton In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor. SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461 J Pharmacol Exp Ther 283 1997 157 163
12. R.H. Knopp, H. Gitter, T. Truitt, H. Bays, C.V. Manion, and L.J. Lipka Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia Eur Heart J 24 2003 729 741
13. M. Van Heek, C. Farley, and D.S. Compton Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function Br J Pharmacol 134 2001 409 417
14. H.R. Davis Jr., L.J. Zhu, L.M. Hoos, G. Tetzloff, M. Maguire, and J. Liu Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis J Biol Chem 279 2004 33586 33592
15. S.W. Altmann, H.R. Davis Jr., L.J. Zhu, X. Yao, L.M. Hoos, and G. Tetzloff Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption Science 303 2004 1201 1204
16. H.E. Bays, P.B. Moore, M.A. Drehobl, S. Rosenblatt, P.D. Toth, and C.A. Dujovne Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies Clin Ther Study 23 2001 1209 1230
17. S. Clauss, K.M. Wai, R.E. Kavey, and K. Kuehl Ezetimibe treatment of pediatric patients with hypercholesterolemia J Pediatr 154 2009 869 872
18. D. Yeste, P. Chacón, and M. Clemente Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents J Pediatr Endocrinol Metab 22 2009 487 492
19. R.E.W. Kavey, V. Allada, S.R. Daniels, L.L. Hayman, B.W. McCrindle, and J.W. Newburger Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics 114 2006 2710 2738
20. S. Wierzbicki, S. Humphries, R. Minhas on behalf of the Guideline Development Group Familial hypercholesterolaemia: summary of NICE guidance BMJ 337 2008 a1095